Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7410062 | 0.68 | SMN1; SMN2 (0.37) | SMN1; SMN2LMNARAB9ANPC1MAPK1 | |
| SCHEMBL11597369 | 0.60 | TSHR (0.48) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| Hydrochloric Acid SCHEMBL2865007 | 0.59 | TSHR (0.67) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| SCHEMBL26740103 | 0.58 | — | — | |
| Hydrochloric Acid SCHEMBL28489957 | 0.57 | TSHR (0.63) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| Hydrochloric Acid SCHEMBL27268436 | 0.57 | TSHR (0.63) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| Hydrochloric Acid SCHEMBL28001216 | 0.57 | TSHR (0.63) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| SCHEMBL4442483 | 0.56 | — | — | |
| SCHEMBL28748446 | 0.56 | TSHR (0.71) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| SCHEMBL8600029 | 0.56 | TSHR (0.71) | SMN1; SMN2LMNAALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293510-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) | 2007-12-20 | — | — | US | disclosed |
| US-7273879-B2 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293510-A1 | Thiadiazole compounds and use thereof | C5, C3AR1, TH | SMN1; SMN2 3891/4885LMNA 3325/4885ALDH1A1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.